药物诱导的自身免疫样肝炎的研究进展  

Research advances in drug-induced autoimmune-like hepatitis

作　　者：李勤荣 尧颖[2] 徐智媛[1] LI Qinrong;YAO Ying;XU Zhiyuan(Department of Gastroenterology,The Second Affiliated Hospital of Kunming Medical University,Kunming 650000,China;Department of Gastroenterology,Yan’an Hospital Affiliated to Kunming Medical University,Kunming 650051,China)

机构地区：[1]昆明医科大学第二附属医院消化内科,昆明650000 [2]昆明医科大学附属延安医院消化内科,昆明650051

出　　处：《临床肝胆病杂志》2024年第6期1255-1258,共4页Journal of Clinical Hepatology

基　　金：国家自然科学基金(82160106)。

摘　　要：药物诱导的自身免疫样肝炎(DI-ALH)是药物性肝损伤的一种特殊临床表型,与自身免疫性肝炎有相似的临床特征和实验室检查,多数时候通过肝组织活检也无法直接区分,因此正确鉴别DI-ALH与自身免疫性肝炎是临床实践中的重难点。本文总结了DI-ALH的发病机制、临床特点、诊治、预后的研究进展,为临床医生提供此类疾病的诊治思路。Drug-induced autoimmune-like hepatitis(DI-ALH)is a special clinical phenotype of drug-induced liver injury and has similar clinical features and laboratory test results to autoimmune hepatitis,and it is often difficult to distinguish them through liver biopsy.Therefore,correct differential diagnosis DI-ALH and autoimmune hepatitis is a crucial and difficult point in clinical practice.This article analyzes the research advances in the pathogenesis,clinical features,diagnosis and treatment,and prognosis of DI-ALH,in order to provide ideas for the diagnosis and treatment of such diseases among clinicians.

关 键 词：化学性与药物性肝损伤 肝炎 自身免疫性 诊断 治疗学 

分 类 号：R575[医药卫生—消化系统]